1-(3-chloro-2-pyridinyl)-3-methyl-piperazine | 1017789-43-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(3-chloro-2-pyridinyl)-3-methyl-piperazine
• 英文别名: 1-(3-chloro-2-pyridyl)-3-methyl-piperazine；1-(3-Chloropyridin-2-yl)-3-methylpiperazine
• CAS: 1017789-43-3
• 化学式: C₁₀H₁₄ClN₃
• 分子量: 211.694
• InChiKey: ZIHUFGHPYQTYIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-(叔丁氧基羰基)-1-噁-2,8-二氮杂螺[4.5]-2-癸烯-3-羧酸 、 1-(3-chloro-2-pyridinyl)-3-methyl-piperazine 在 1-羟基苯并三唑 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 以60%的产率得到3-[4-(3-chloropyridin-2-yl)-2-methyl-piperazin-1-carbonyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  WO2006/122769

  摘要：

  公开号：
• 作为产物：
  描述：

  3-(三甲基硅烷基)苯胺 、 2,3-二氯吡啶 、 、 (R)-(-)-2-甲基哌嗪 、 生成 1-(3-chloro-2-pyridinyl)-3-methyl-piperazine
  参考文献：
  名称：

  Compounds as TRPV1 antagonists, pharmaceutical compositions and medical uses thereof

  摘要：

  本发明公开了一种新的化合物及其药用可接受盐和水合物。同时，提供了该药物组合物的制备方法。此外，还公开了该化合物、药用可接受盐和水合物以及药物组合物在治疗TRPV1介导的疾病方面的医疗用途。

  公开号：

  US08748610B2

文献信息

• [EN] BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS<br/>[FR] DERIVES DE BENZIMIDAZOLES ET UTILISATION DE CEUX-CI EN TANT QUE LIGANDS DU RECEPTEUR VANILLOIDE
  申请人：AMGEN INC

  公开号：WO2004035549A1

  公开（公告）日：2004-04-29

  Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.

  式（I）的化合物在治疗辣椒素受体介导的疾病方面很有用，如炎症性或神经病痛以及涉及感觉神经功能的疾病，如哮喘、类风湿性关节炎、骨关节炎、炎症性肠道疾病、尿失禁、偏头痛和牛皮癣。
• [EN] ORGANOSILICON COMPOUNDS AND THEIR USE AS THE MODULATORS OF THE TRPV1 RECEPTOR<br/>[FR] COMPOSÉS D'ORGANOSILICIUM ET LEUR UTILISATION EN TANT QUE MODULATEURS DU RÉCEPTEUR TRPV1
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010092342A1

  公开（公告）日：2010-08-19

  A compound having the Formula (1): wherein: X1, X2, X3 and X4 independently represent CH or N; R1, R2 and R3 independently represent C1-6 alkyl, C3-8 cycloalkyl or C3-8 cycloalky IC1-6alkyl, each of which groups may be optionally substituted with one or more substituents independently selected from halogen and haloC1-6 alkyl; R4, R5, R6, R7, R8 and R9 independently represent H, C1-6 alkyl, C3-8 cycloalkyl or -QI-OR14, or R4 and R9 may join to form a bridging C1-6 alkylene chain; R10 represents aryl or heteroaryl, each of which may be optionally substituted by one or more substituents, independently selected from halogen, C1-6 alkyl, haloC1-6 alkyl, hydroxyC1-6alkyl, haloC1-6 alkoxy, cyano, -Q2-CO2R12, -Q2-COR12, -Q2-CONR12R13, -Q2-OR12, -Q2-NR12Rn, -Q2-NR12SO2R13, -Q2- NR12COR13, -Q2-SO2NR12R13, -Q2-S(O)mR12, -Y-aryl, -Y-heteroaryl, -Y-C3-8 cycloalkyl and -Y-heterocyclyl; Q1 and Q2 independently represent a covalent bond, C1-6 alkylene, or 1-6 alkylene substituted with hydroxy; R12 and R13 independently represent a H atom, or a C1-6 alkyl or C3-8 cycloalkyl group, in which each group may be optionally substituted with one or more C1-6 alkoxy; or when R12 and R13 are attached to the same nitrogen atom they may join to form a nitrogen containing heterocyclyl ring, which may be optionally substituted with one or more substituents independently selected from C1-6 alkyl and C1-6 alkoxy; R14 represents a H atom, or a C1-6 alkyl or C3-8 cycloalkyl group, in which each group may be optionally substituted with one or more C1-6 alkoxy; Y represents a covalent bond, C1-6 alkylene, or -O-. m represents 0, 1 or 2; R11, which is optionally present and may be attached to any available carbon atom X1 to X4 instead of H, represents halogen, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, cyano or C1-6 alkyl which may be optionally substituted with one or more substituents independently selected from halogen, haloC1-6 alkyl and OR16; q represents 0, 1 or 2; W represents -(CH2)n-, which may be optionally substituted with one or more substituents independently selected from C1-6 alkyl, C3-8 cycloalkyl and -Q3-OR15; n represents 1 or 2; Q3 represents a covalent bond or C1-6 alkylene; R15 represents H, C1-6 alkyl, or C3-8 cycloalkyl; R16 is as defined for R14; or a pharmaceutically acceptable salt or ester thereof. Uses of the compounds as modulators of the TrpVl receptor are also disclosed.

  一种具有以下化学式（1）的化合物：其中：X1、X2、X3和X4分别代表CH或N；R1、R2和R3分别代表C1-6烷基，C3-8环烷基或C3-8环烷基C1-6烷基，每个基团可以选择性地被一个或多个取代基取代，所述取代基独立地选自卤素和卤代C1-6烷基；R4、R5、R6、R7、R8和R9分别代表H、C1-6烷基，C3-8环烷基或-QI-OR14，或者R4和R9可以连接形成一个桥接的C1-6亚烷基链；R10代表芳基或杂环芳基，每个基团可以选择性地被一个或多个取代基取代，独立地选自卤素、C1-6烷基、卤代C1-6烷基、羟基C1-6烷基、卤代C1-6烷氧基、氰基、-Q2-CO2R12、-Q2-COR12、-Q2-CONR12R13、-Q2-OR12、-Q2-NR12Rn、-Q2-NR12SO2R13、-Q2-NR12COR13、-Q2-SO2NR12R13、-Q2-S(O)mR12、-Y-芳基、-Y-杂环芳基、-Y-C3-8环烷基和-Y-杂环烷基；Q1和Q2独立地代表共价键、C1-6亚烷基或用羟基取代的1-6亚烷基；R12和R13独立地代表H原子，或C1-6烷基或C3-8环烷基基团，其中每个基团可以选择性地被一个或多个C1-6烷氧基取代；或者当R12和R13连接到同一个氮原子时，它们可以连接形成一个含氮的杂环烷基环，该环可以选择性地被一个或多个取代基取代，独立地选自C1-6烷基和C1-6烷氧基；R14代表H原子，或C1-6烷基或C3-8环烷基基团，其中每个基团可以选择性地被一个或多个C1-6烷氧基取代；Y代表共价键、C1-6亚烷基或-O-。m代表0、1或2；R11（可选地出现并且可以连接到任何可用的碳原子X1到X4代替H）代表卤素、卤代C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、氰基或C1-6烷基，可以选择性地被一个或多个取代基取代，独立地选自卤素、卤代C1-6烷基和OR16；q代表0、1或2；W代表-(CH2)n-，可以选择性地被一个或多个取代基取代，独立地选自C1-6烷基、C3-8环烷基和-Q3-OR15；n代表1或2；Q3代表共价键或C1-6亚烷基；R15代表H、C1-6烷基或C3-8环烷基；R16如R14所定义；或其药学上可接受的盐或酯。还公开了该化合物作为TrpV1受体调节剂的用途。
• Capsaicin receptor ligands
  申请人：——

  公开号：US20020132853A1

  公开（公告）日：2002-09-19

  Disclosed are diaryl piperazines and related compounds. These compounds are selective modulators of capsaicin receptors, including human capsaicin receptors, that are, therefore, useful in the treatment of a chronic and acute pain conditions, itch and urinary incontinence. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of capsaicin receptors and as standards in assays for capsaicin receptor binding and capsaicin receptor mediated cation conductance. Methods of using the compounds in receptor localization studies are given.

  揭示了二芳基哌嗪和相关化合物。这些化合物是辣椒素受体的选择性调节剂，包括人类辣椒素受体，在慢性和急性疼痛症状、瘙痒和尿失禁的治疗中非常有用。还提供了治疗这些疾病的方法以及包装的药物组合物。该发明的化合物还可用作辣椒素受体的定位探针，并作为辣椒素受体结合和辣椒素受体介导的阳离子传导的测定中的标准。提供了使用这些化合物进行受体定位研究的方法。
• Compounds as TRVP1 Blockers, Pharmaceutical Compositions and Medical Uses Thereof
  申请人：Sun Qun

  公开号：US20120184509A1

  公开（公告）日：2012-07-19

  A kind of new compounds, and their pharmaceutically acceptable salts, and hydrates are disclosed. The pharmaceutical composition thereof is also provided. And also are the medical uses of the compounds, pharmaceutically acceptable salts, hydrates and the pharmaceutical composition for treating the TRPV1-mediate diseases.

  披露了一种新化合物及其药用盐和水合物。还提供了这些药物组合物。还提供了这些化合物、药用盐、水合物和药物组合物用于治疗TRPV1介导疾病的医疗用途。
• [EN] BENZOAZOLYPIPERAZINE DERIVATIVES HAVING MGLUR1- AND MGLUR5-ANTAGONISTIC ACTIVITY<br/>[FR] DERIVES DE BENZOAZOLYLPIPERAZINE PRESENTANT UNE ACTIVITE ANTAGONISTE VIS-A-VIS DE MGLUR1 ET DE MGLUR5
  申请人：EURO CELTIQUE SA

  公开号：WO2004058754A1

  公开（公告）日：2004-07-15

  A compound of formula (I) wherein Ar1, A, R3, x, and m are as disclosed herein and Ar2 is a benzothiazolyl, benzooxazolyl, or benzoimidazolyl group or a pharmaceutically acceptable salt thereof (a “Benzoazolylpiperazine Compound”), compositions comprising a Benzoazolylpiperazine Compound, and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson’s disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, retricted brain function, Huntington’s chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of Benzoazolylpiperazine Compound are disclosed.

  公式（I）的化合物，其中Ar1，A，R3，x和m如本文所述，Ar2是苯并噻唑基，苯并噁唑基或苯并咪唑基或其药学上可接受的盐（“苯并咪唑基哌嗪化合物”），包含苯并咪唑基哌嗪化合物的组合物，并且揭示了治疗或预防疼痛，UI，溃疡，IBD，IBS，成瘾障碍，帕金森病，帕金森综合症，焦虑，癫痫，中风，癫痫发作，瘙痒症，精神病，认知障碍，记忆力缺失，受限的脑功能，亨廷顿舞蹈症，肌萎缩性侧索硬化症，痴呆症，视网膜病变，肌肉痉挛，偏头痛，呕吐，运动失调或抑郁症的方法，包括向需要治疗的动物中投与有效量的苯并咪唑基哌嗪化合物。